tiprankstipranks

Okyo Pharma files for FTD with FDA for urcosimod

OKYO Pharma (OKYO) announces the filing of its application for Fast Track designation, FTD, with the U.S. Food and Drug Administration, FDA, for urcosimod for the treatment of neuropathic corneal pain, which is a debilitating condition affecting many tens of thousands worldwide, and is characterized by chronic, severe eye discomfort for which there is no FDA-approved, effective treatment.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue